🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We leave #ASCO25 with full hearts and minds brimming with science. Presenting #TUXEDO3trial, sharing #ADELAtrial & #WINBtrial, and connecting with passionate people, this is what drives us. Thank you all. We take home more than results. Time to rest… until next time!

📢 New publication in Nature Medicine! The phase 2 #ATRACTIB trial tested atezolizumab + paclitaxel + bevacizumab as 1L for advanced TNBC, regardless of PD-L1 status. 🕒 Median PFS: 11 months 🎯 ORR: 63% 🔗 Read the full article here 👉🏼 lnkd.in/g2fsyzeX #BreastCancer

📢 A new chapter for the #PARSIFALLong study! Long-term results now published in The Lancet Regional Health Europe, a major milestone for HR+/HER2- ABC. 👉 Read more: sciencedirect.com/science/articl…

From #ESMOGI25, Queralt Serra highlights the importance of connecting with collaborators, championing our concepts, and staying up to date with the latest advances that move the field forward.

Last week, we wrapped up our participation in the #ESMOGi25 with this team photo, a reflection of the commitment and passion that unite us at #MEDSIR. Thank you to everyone who joined us throughout these days. We keep moving forward together.

#ISTs Innovation Forum — Applications are still open! Don't miss this unique opportunity to connect, learn and innovate in lung cancer clinical trials. 📅 Sept 6 | 🕕 6:00 PM 📲 Apply now via the flyer link or QR code: medsir.org/events/istsfor… 👀 Only 25 spots available!